Neo Ivy Capital Management Novavax Inc Transaction History

Neo Ivy Capital Management

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$18.2 - $76.12 $36,782 - $153,838	2,021 New	2,021 $37,000
Q2 2022 Aug 16, 2022	SELL	$36.28 - $75.29 $48,905 - $101,490	-1,348 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$69.73 - $142.9 $82,351 - $168,764	1,181 Added 707.19%	1,348 $100,000
Q4 2021 Feb 15, 2022	SELL	$134.56 - $217.97 $13,321 - $21,579	-99 Reduced 37.22%	167 $23,000
Q3 2021 Nov 16, 2021	SELL	$177.8 - $270.58 $59,029 - $89,832	-332 Reduced 55.52%	266 $22,000
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $72,358 - $154,086	598 New	598 $127,000
Q1 2021 Oct 07, 2021	SELL	$112.98 - $319.93 $40,559 - $114,854	-359 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$78.74 - $139.5 $28,110 - $49,801	357 Added 17850.0%	359 $40,000
Q3 2020 Nov 17, 2020	BUY	$79.44 - $178.51 $158 - $357	2 New	2 $0
Q2 2020 Aug 17, 2020	SELL	$13.86 - $83.61 $3,686 - $22,240	-266 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$13.86 - $83.61 $3,686 - $22,240	266 New	266 $22,000

284

84.8M

5.43M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $731M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.